secwatch / observer

8-K filed May 22, 2026, 9:03 AM ET ticker ONCY CIK 0001129928

other material confidence medium sentiment positive materiality 0.55

Oncolytics posts translational data from GOBLET/AWARE-1 at ASCO 2026 supporting pelareorep immune activation

ONCOLYTICS BIOTECH INC

Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.
In pancreatic cancer, expansion of pre-existing TIL clones correlated with tumor volume reduction; mutant KRAS-specific T-cell clones expanded.
In breast cancer, increased antiviral/immune gene expression, CXCL13 induction, and tertiary lymphoid structure formation by imaging mass cytometry.
Abstract 'Influence of pelareorep on mutant KRAS-specific blood TIL clonal expansion' (No. 2664) presented May 30, 1:30-4:30 p.m. CT.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001129928-26-000035
form_type: 8-K
ticker: ONCY
cik: 0001129928
company_name: ONCOLYTICS BIOTECH INC
filed_at: 2026-05-22T13:03:22+00:00
discovered_at: 2026-05-22T13:04:00.313188+00:00
generated_at: 2026-05-22T13:04:40.096530+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: medium
secwatch_canonical_url: https://secwatch.observer/filing/0001129928-26-000035
json_url: https://secwatch.observer/filing/0001129928-26-000035.json
markdown_url: https://secwatch.observer/filing/0001129928-26-000035.md
text_url: https://secwatch.observer/filing/0001129928-26-000035.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000035/0001129928-26-000035-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000035/oncy-20260522.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BUKS

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

BUTLER NATIONAL CORP June 1, 2026, 12:41 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ONCY

Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned

ONCOLYTICS BIOTECH INC June 1, 2026, 9:06 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CLIR

ClearSign Technologies prices 777,780-share public offering at $4.33/share for ~$3.37M gross proceeds

ClearSign Technologies Corp June 1, 2026, 8:30 AM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001129928-26-000035

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.